Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.

De Laurentiis, MichelinoBorstnar, SimonaCampone, MarioWarner, EllenBofill, Javier SalvadorJacot, WilliamDent, SusanMartin, MiguelRing, AlistairCottu, PaulLu, JaniceCiruelos, EvaAzim, Hamdy AChatterjee, SanjoyZhou, KatieWu, JiwenMenon-Singh, LakshmiZamagni, Claudio2025-01-072025-01-072022https://hdl.handle.net/10668/27207enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.research article34625861open access10.1007/s10549-021-06374-61573-7217PMC8758655https://link.springer.com/content/pdf/10.1007/s10549-021-06374-6.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8758655/pdf